Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1398.4%.

  • Avidity Biosciences' EBITDA Margin rose 17198700.0% to 1398.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 2660.15%, marking a year-over-year increase of 235400.0%. This contributed to the annual value of 2932.23% for FY2024, which is 7418800.0% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' EBITDA Margin is 1398.4%, which was up 17198700.0% from 4114.97% recorded in Q2 2025.
  • Avidity Biosciences' 5-year EBITDA Margin high stood at 881.73% for Q1 2021, and its period low was 7368.66% during Q1 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 2079.53% (2023), whereas its average is 2470.0%.
  • The largest annual percentage gain for Avidity Biosciences' EBITDA Margin in the last 5 years was 17198700bps (2025), contrasted with its biggest fall of -54086200bps (2025).
  • Quarter analysis of 5 years shows Avidity Biosciences' EBITDA Margin stood at 2090.93% in 2021, then rose by 14bps to 1795.09% in 2022, then crashed by -48bps to 2664.84% in 2023, then crashed by -34bps to 3580.79% in 2024, then skyrocketed by 61bps to 1398.4% in 2025.
  • Its last three reported values are 1398.4% in Q3 2025, 4114.97% for Q2 2025, and 7368.66% during Q1 2025.